Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension

S. R. Shah, S. M. Gressett Ussery, J. E. Dowell, E. Marley, J. Liticker, Y. Arriaga, U. Verma

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Background: A previous study has shown that shorter bevacizumab infusions (0.5 mg/kg/min) can be safely administered without increasing the risk of infusion-related hypersensitivity reactions (HSRs). However, the risk of proteinuria and hypertension in patients receiving shorter infusions of bevacizumab is undetermined. Patients and methods: This was a multicenter, prospective, observational study in patients receiving <10 mg/kg of bevacizumab infused over 0.5 mg/kg/min. Patients were observed until discontinuation of bevacizumab for progression of cancer or toxicity. The incidence of hypertension and proteinuria was compared with a prior cohort of patients who had received standard duration infusions of bevacizumab. Results: Sixty-three patients received a total of 392 doses of shorter bevacizumab infusions. Nineteen (30.2) patients experienced proteinuria while receiving bevacizumab. Out of 19 patients, 13 had grade 1 and 6 had grade 2 proteinuria. None of the patients experienced grade 3 or 4 proteinuria. Hypertension was reported in 32 (50.8) patients receiving bevacizumab. Twelve (19) patients developed grade 3 or greater hypertension on bevacizumab. The incidence of proteinuria and hypertension was 38.3 and 56.6, respectively, in patients (N 120, 1347 infusions) receiving standard duration infusions of bevacizumab. Conclusions: Shorter bevacizumab infusions (0.5 mg/kg/min) do not increase the risk of proteinuria and hypertension.

Original languageEnglish (US)
Pages (from-to)960-965
Number of pages6
JournalAnnals of Oncology
Volume24
Issue number4
DOIs
StatePublished - Apr 2013

Keywords

  • Administration
  • Bevacizumab
  • Colorectal cancer
  • Hypertension
  • Infusion
  • Proteinuria

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension'. Together they form a unique fingerprint.

Cite this